Clinical Trials

Carcinoma, Non-Small-Cell Lung

NCT02443324 2024-07-31

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

GastrointestinalGenitourinaryThoracic

175 enrolled 23 charts

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03921671 2024-05-29

RELEVENT

Phase 2 Unknown

60 enrolled

Other solid neoplasmThoracic

Neoplasm Metastasis, Thymoma

NCT03502746 2024-05-14

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Phase 2 Terminated

34 enrolled 11 charts

Mesothelioma, Malignant

NCT02789345 2024-02-05

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

29 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT04151563 2023-12-19

CheckMate 79X

Phase 1/2 Withdrawn

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05800418 2023-04-05

Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers

88 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Stomach Neoplasms

NCT03904108 2022-05-26

Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy

Phase 2 Terminated

3 enrolled 6 charts

Carcinoma, Non-Small-Cell Lung

NCT05007769 2021-11-05

RAN

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02572687 2021-01-20

A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

GastrointestinalGenitourinaryThoracic

85 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Neoplasm Metastasis, Stomach Neoplasms

NCT02082210 2020-12-19

A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer

Phase 1/2 Completed

97 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Liver Neoplasms

NCT02730247 2020-11-19

Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

7 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT02079636 2020-09-11

A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)

142 enrolled 36 charts

Carcinoma, Non-Small-Cell Lung

NCT02831491 2020-06-09

A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01703091 2019-09-30

A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer

197 enrolled 12 charts

Non-small Cell Lung Cancer Metastatic

NCT01168973 2019-09-25

A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

Phase 3 Completed

1,253 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01160744 2019-09-13

A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

280 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00735696 2014-12-29

A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer

41 enrolled 17 charts